Comparative pharmaco-economic assessment of apixaban versus standard of care for the prevention of stroke in italian atrial fibrillation patients
Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 15-25
Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients
Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(Suppl 1): 5-14
Cost effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in italian atrial fibrillation patients
Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(4): 101-112
Cost-effectiveness of blood culture and a multiplex real-time pcr in hematological patients with suspected sepsis: an observational propensity score-matched study
Mancini N, Sambri V, Corti C, Ghidoli N, Tolomelli G, Paolucci M, Clerici D, Carletti S, Greco R, Tassara M, Pizzorno B, Zaniolo O, Povero M, Pradelli L, Burioni R, Stanzani M, Landini MP, Ciceri F, Clementi M. – Expert Rev Mol Diagn 2014; 14(5): 623-32
Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model
Pradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. – Clin Nutr 2014; 33(5): 785-92
Real-life cost and cost-effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48-month survey
Povero M, Pradelli L, Turco P, Dal Negro RW. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(2): 39-44
The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban
Pradelli L., Calandriello M., Di Virgilio R., Bellone M., Tubaro M. – Farmeconomia. Health economics and therapeutic pathways 2014; 15(1S): 3-4
